You Need to Buy HEXO (TSX:HEXO) Today!

HEXO Corp’s (TSX:HEXO)(NYSE:HEXO) stock price has tumbled this year. Is this a good RRSP or TFSA stock?

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Generally speaking, I am not big on recommending stocks in the marijuana industry.

The reason for this is because the marijuana industry is so inflated, I find it hard to find a company that has a strong underlying business and a competitive advantage in the crowded industry.

That said, HEXO (TSX:HEXO)(NYSE:HEXO) is a game changer in the marijuana industry. For those of you unfamiliar with the company, it is a consumer packaged goods cannabis company specializing in ease-of-use marijuana products.

Its brands include the eponymously named HEXO, the sublingual mist product line Elixir, the fine-milled cannabis line Decarb and the typical dried cannabis. On a purely revenue basis, the company is the sixth-largest marijuana company in North America.

Its reputation has helped the company secure a $65 million syndicated credit facility with CIBC and BMO, which gives credibility to HEXO.

The reason why HEXO is worth your investment is due to its price point and its increasing revenues.

Attractive price point

Let’s face it, at $32.85 a share, Canopy Growth’s stock prices out a lot of investors. If you were to buy just 100 shares of Canopy Growth, you would be paying over $3,000!

I don’t know about you, but for investors like me, that’s a significant chunk of my portfolio. Unlike Canopy Growth, HEXO is priced at $5.46 a share, which means 100 shares will only set you back $546.

In the investing world, it has been said that returns should be based on percentages — not values; however, I beg to differ.

Think of it this way: if you’ve put $3,285 into Canopy Growth (essentially buying 100 shares) and it goes down by 10%, you’ve lost $329.

If you purchased 100 shares of HEXO for $546 and it declined 10%, you would lose $55. As you can see, the amount of risk you’re exposed to at HEXO’s price point is much less than Canopy Growth. At the end of the day, both stocks are in the marijuana industry, which means the volatility for the two would be comparable, but at least with HEXO, you’ll still have money left in your portfolio.

Steadily increasing revenues

I was pleasantly surprised to see HEXO’s revenues increasing since fiscal 2016.

From fiscal 2016 to fiscal 2018, its revenues have grown from $1.87 million to $4.93 million for a compounded annual growth rate of 38.14%!

Given that Canopy Growth lost $1.2 billion in one quarter this year, HEXO is definitely showing it’s healthier and better managed than its competitor.

Admittedly, the company took a net loss of $23 million in fiscal 2018, which is not ideal; however, the company’s competitive advantage by targeting the ease-of-use market puts it several steps ahead of Canopy Growth, even with its net loss.

Summary

Investors have definitely overlooked HEXO during the marijuana craze partially due to its comparatively small market capitalization at $1.4 billion.

This is advantageous for people like you who are reading this article, as HEXO is currently trading at an attractive price point, and it is showing signs of steady revenue growth.

Both these traits coupled with its focus on the ease-of-use market put HEXO in a strong position, where it can grow and deliver solid returns to investors.

If you liked this article, click the link below for exclusive insight.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chen Liu has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »